A busy 2016 saw three new biosimilars released as a part of 22 total new US drug approvals. With a multitude of mergers, acquisitions, and facility expansions dominating headlines, 2016 also saw major stories on drug pricing, immunotherapy, and the opioid epidemic. Learn more in this year’s clinical drug development and manufacturing year in review.
View File